KRAS and familial pancreatic carcinoma: In line with the supposed mechanisms of action, neither KRAS inhibition by means of AMG510 nor MEK inhibition with Binimetinib showed any tangible reduction in clonogenicity on KRAS wild type BxPC3 pancreatic cancer cells, and there was no additive or synergistic effect upon combination with irradiation (Figure 2e,f).